LOGIN  |  REGISTER

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young...

March 28
Last Trade: 73.25 0.24 0.33

Efficacy and Safety Profile of Once-Daily Vemlidy Demonstrated in Children Six Years of Age (Weighing at Least 25kg) and Older  FOSTER CITY, Calif. / Mar 28, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has...Read more


Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia

March 28
Last Trade: 6.80 -0.05 -0.73

NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and...Read more


Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal...

March 28
Last Trade: 1.79 -0.01 -0.56

MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the resubmission of its New Drug Application...Read more


FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of...

March 28
Last Trade: 54.23 0.98 1.84

Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer PRINCETON, N.J. / Mar 28,...Read more


Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with...

March 28
Last Trade: 54.23 0.98 1.84

PRINCETON, N.J. / Mar 28, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia (ozanimod) in adult patients...Read more


Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans...

March 28
Last Trade: 1.40 0.62 79.49

Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group The data supports the Company’s strategy to offer military and civilian physicians a new tool to effectively treat mTBI without the use of...Read more


Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Biggest Gainers

 
CompanyChangeLast Trade
Avalo Therapeutics 17.00 357.89 $21.75
Atrion 15.55 3.47 $463.55
Madrigal Pharmaceuticals 8.23 3.18 $267.04
ZIVO Bioscience 6.65 604.55 $7.75
ICON 6.45 1.96 $335.95
Encompass Health 4.87 6.27 $82.58
ICU Medical 4.43 4.31 $107.32
CervoMed 3.68 18.76 $23.30
Corbus Pharmaceuticals 3.67 10.32 $39.24
Celcuity 3.44 18.94 $21.60
SIGA Technologies 3.12 57.35 $8.56
ShockWave Medical 3.02 0.94 $325.63
Ascendis Pharma 2.73 1.84 $151.17
Guardant Health 2.67 14.87 $20.63
Outlook Therapeutics 2.57 27.43 $11.94
Crinetics Pharmaceuticals 2.38 5.36 $46.81
Masimo 2.37 1.64 $146.85

Highest Volume

 
CompanyVolumeLast Trade
Biodexa Pharmaceuticals 87,771,818 $1.62
Gamida Cell 85,160,990 $0.04
Akebia Therapeutics 60,390,756 $1.83
Jaguar Health 57,461,954 $0.09
iBio 50,345,903 $4.06
Roivant 45,598,596 $10.54
Ontrak 43,431,813 $0.51
Pfizer 37,945,473 $27.75
Xilio Therapeutics 33,360,758 $1.08
Walgreens Boots Alliance 32,796,379 $21.69
Kintara Therapeutics 31,453,911 $0.10
Avalo Therapeutics 31,043,413 $21.75
OPKO Health 28,867,233 $1.20
Ginkgo Bioworks 25,864,540 $1.16
Tonix Pharmaceuticals 21,062,539 $0.19
Mesoblast 14,005,572 $5.01
Bristol-Myers Squibb 12,455,610 $54.23
  • Upcoming FDA Catalysts

    • Vertex Pharmaceuticals (NASDAQ: VRTX) PDUFA Date

      March 30, 2024
    • CRISPR Therapeutics (NASDAQ: CRSP) PDUFA Date

      March 30, 2024
    • Rocket Pharmaceuticals (NASDAQ: RCKT) PDUFA Date

      March 31, 2024
    • Regeneron Pharmaceuticals (NASDAQ: REGN) Data Presentation

      March 31, 2024
    • Verrica Pharmaceuticals (NASDAQ: VRCA) Data Presentation

      April 1, 2024
    • Delcath Systems (NASDAQ: DCTH) Data Presentation

      April 1, 2024

Featured Stock

Surmodics

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities:

COPYRIGHT ©2023 HEALTH STOCKS HUB